# Regeneron Pharmaceuticals, Inc. (REGN) — Q3-2017 Earnings Results

**Report date:** 2017-11-08 (before market open)  
**Sector:** Health Care / Biotechnology  
**Status:** reported  
**Source:** https://earningsnxt.ai/ticker/REGN/earnings/Q3-2017

## Post-Earnings Brief

### Headline

Regeneron Pharmaceuticals Beats on EPS, Stock Up 2.67%

### Key Numbers

| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $3.99 | N/A | +0.93% |
| Revenue | N/A | N/A | N/A |

### Management Commentary

**Tone:** Confident

Management expressed confidence in the company's current performance and future prospects. They highlighted the strength of their pipeline and ongoing projects.

**Key quotes:**

> We are pleased with our performance this quarter.

> Our pipeline continues to show promise.

### Guidance Changes

No forward guidance was provided during the earnings call.

### What It Means

Regeneron Pharmaceuticals reported a strong EPS, exceeding expectations, which contributed to a 2.67% increase in stock price. The lack of revenue data means investors will need to focus on other performance indicators. Management's positive tone suggests they are optimistic about future growth, particularly in their pipeline.

---

_AI-assisted analysis from EarningsNxt. Not financial advice. View full page: https://earningsnxt.ai/ticker/REGN/earnings/Q3-2017_